Targets › PDE5A
32 programs from 31 companies in 40 trials: 16 Phase 2, 11 Phase 4, 9 Phase 3, 4 Phase 1; Cardiovascular, Genitourinary, Other; next expected readout Nov 2026.
Plays a role in signal transduction by regulating the intracellular concentration of cyclic nucleotides. This phosphodiesterase catalyzes the specific hydrolysis of cGMP to 5'-GMP. Specifically regulates nitric-oxide-generated cGMP. (UniProt, O76074)
Open in Phaseline: the race on PDE5A, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Beni-Suef University | Tadalafil Phosphodiesterase 5A inhibitor | PDE5A | Phase 4 | IVF; Erectile Dysfunction; Acute Urinary Retention | Nov 2026 |
| St Joseph University, Beirut, Lebanon | Pentoxifylline Adenosine A2 receptor antagonist; 3',5'-cyclic phosphodiesterase inhibitor | ADORA2B, ADORA2A, PDE5A, PDE4A, PDE3A | Phase 4 | Lumbar Radiculopathy | Dec 2026 |
| Mansoura University | Tadalafil Phosphodiesterase 5A inhibitor | PDE5A | Phase 4 | Overactive Bladder (OAB); Erectile Dysfunctions; Erectile Dysfunction | Dec 2026 |
| The Netherlands Cancer Institute | Sildenafil Phosphodiesterase 5A inhibitor | PDE5A | Phase 4 | Erectile Dysfunction Following Radical Prostatectomy | Jan 2027 |
| VA Office of Research and Development | Pentoxifylline Adenosine A2 receptor antagonist; 3',5'-cyclic phosphodiesterase inhibitor | ADORA2B, ADORA2A, PDE5A, PDE4A, PDE3A | Phase 4 | Diabetic Kidney Disease | Jan 2028 |
| University of Sao Paulo General Hospital | Sildenafil Phosphodiesterase 5A inhibitor | PDE5A | Phase 4 | Pulmonary Arterial Hypertension (PAH) | Jul 2028 |
| Vastra Gotaland Region | Dipyridamole Equilibrative nucleoside transporter 1 inhibitor; 3',5'-cyclic phosphodiesterase inhibitor | SLC29A1, PDE5A, PDE4A, PDE3A, PDE6H | Phase 4 | Takotsubo Syndrome | Dec 2028 |
| Eric A. Hoffman | Sildenafil Phosphodiesterase 5A inhibitor | PDE5A | Phase 4 | Emphysema | – |
| Al-Azhar University | Pentoxifylline Adenosine A2 receptor antagonist; 3',5'-cyclic phosphodiesterase inhibitor | ADORA2B, ADORA2A, PDE5A, PDE4A, PDE3A | Phase 3 | Chronic Kidney Diseases | Dec 2026 |
| Tanta University | Pentoxifylline Adenosine A2 receptor antagonist; 3',5'-cyclic phosphodiesterase inhibitor | ADORA2B, ADORA2A, PDE5A, PDE4A, PDE3A | Phase 3 | IBS - Irritable Bowel Syndrome; Rheumatoid Arthritis | May 2027 |
| Assistance Publique - Hôpitaux de Paris | Tadalafil Phosphodiesterase 5A inhibitor | PDE5A | Phase 3 | Pulmonary Hypertension; Pulmonary Arterial Hypertension (PAH) | Oct 2027 |
| University Hospital, Rouen | Sildenafil Phosphodiesterase 5A inhibitor | PDE5A | Phase 3 | Rectal Cancer | Feb 2030 |
| University of Washington | Pentoxifylline Adenosine A2 receptor antagonist; 3',5'-cyclic phosphodiesterase inhibitor | ADORA2B, ADORA2A, PDE5A, PDE4A, PDE3A | Phase 3 | Medication-related Osteonecrosis of the Jaw | – |
| Rennes University Hospital | Sildenafil citrate Phosphodiesterase 5A inhibitor | PDE5A | Phase 3 | Peripheral Artery Disease | – |
| Mezzion Pharma | Udenafil Phosphodiesterase 5A inhibitor | PDE5A | Phase 3 | Single Ventricle Heart Disease | – |
| Beni-Suef University | pentoxifylline Adenosine A2 receptor antagonist; 3',5'-cyclic phosphodiesterase inhibitor | ADORA2B, ADORA2A, PDE5A, PDE4A, PDE3A | Phase 3 | Embryo Transfer | – |
| The University of Texas Medical Branch, Galveston | Sildenafil Citrate Phosphodiesterase 5A inhibitor | PDE5A | Phase 2 | Spinal Cord Injuries; Urinary Incontinence | Dec 2026 |
| Mostafa Bahaa | Pentoxifylline Adenosine A2 receptor antagonist; 3',5'-cyclic phosphodiesterase inhibitor | ADORA2B, ADORA2A, PDE5A, PDE4A, PDE3A | Phase 2 | Epilepsy | Dec 2026 |
| Yunfeng Xia | Dipyridamole Equilibrative nucleoside transporter 1 inhibitor; 3',5'-cyclic phosphodiesterase inhibitor | SLC29A1, PDE5A, PDE4A, PDE3A, PDE6H | Phase 2 | Restless Leg Syndrome Due to Uraemia | Dec 2026 |
| Ihab Elsayed Hassan | Pentoxifylline Adenosine A2 receptor antagonist; 3',5'-cyclic phosphodiesterase inhibitor | ADORA2B, ADORA2A, PDE5A, PDE4A, PDE3A | Phase 2 | Inflammatory Bowel Diseases | Jan 2027 |
| University Hospital, Limoges | Pentoxifylline Adenosine A2 receptor antagonist; 3',5'-cyclic phosphodiesterase inhibitor | ADORA2B, ADORA2A, PDE5A, PDE4A, PDE3A | Phase 2 | Medication-related Osteonecrosis of the Jaw (MRONJ) | Apr 2027 |
| Stanford University | Dipyridamole Equilibrative nucleoside transporter 1 inhibitor; 3',5'-cyclic phosphodiesterase inhibitor | SLC29A1, PDE5A, PDE4A, PDE3A, PDE6H | Phase 2 | Hypophosphatemia | May 2027 |
| University of Alberta | Sildenafil Citrate Phosphodiesterase 5A inhibitor | PDE5A | Phase 2 | Chronic Obstructive Pulmonary Disease | May 2027 |
| University of Pennsylvania | Sildenafil Citrate Phosphodiesterase 5A inhibitor | PDE5A | Phase 2 | Traumatic Brain Injury | Dec 2027 |
| Silvia Ulrich | Sildenafil Phosphodiesterase 5A inhibitor | PDE5A | Phase 2 | Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH) | Apr 2028 |
| M.D. Anderson Cancer Center | Pentoxifylline Adenosine A2 receptor antagonist; 3',5'-cyclic phosphodiesterase inhibitor | ADORA2B, ADORA2A, PDE5A, PDE4A, PDE3A | Phase 2 | Lymphedema; Fibrosis Syndrome | May 2029 |
| Pia Wintermark | Sildenafil Phosphodiesterase 5A inhibitor | PDE5A | Phase 2 | Neonatal Encephalopathy | Oct 2030 |
| University Health Network, Toronto | Pentoxifylline Adenosine A2 receptor antagonist; 3',5'-cyclic phosphodiesterase inhibitor | ADORA2B, ADORA2A, PDE5A, PDE4A, PDE3A | Phase 2 | Non-Small Cell Lung Cancer | Nov 2031 |
| University of Utah | Sildenafil Phosphodiesterase 5A inhibitor | PDE5A | Phase 2 | Congenital Diaphragmatic Hernia | – |
| Children's Mercy Hospital Kansas City | Sildenafil Phosphodiesterase 5A inhibitor | PDE5A | Phase 1 | Fontan Circulation | May 2027 |
| Aspargo Labs | ASP-001.1 (Hezkue Turbo) Phosphodiesterase-5 (PDE-5) inhibitor | PDE5A | Phase 1 | Erectile Dysfunction | – |
| Sohag University | Sildenafil Citrate Phosphodiesterase 5A inhibitor | PDE5A | Phase 1 | Persistent Pulmonary Hypertension of Newborn | – |
Erectile Dysfunction (3) Pulmonary Arterial Hypertension (PAH) (2) IVF (1) Acute Urinary Retention (1) Medication-related Osteonecrosis of the Jaw (1) Medication-related Osteonecrosis of the Jaw (MRONJ) (1) Erectile Dysfunction Following Radical Prostatectomy (1) Persistent Pulmonary Hypertension of Newborn (1) Fontan Circulation (1) Hypophosphatemia (1) Epilepsy (1) Lymphedema (1)
small molecule (31)
Beni-Suef University (2) University of Sao Paulo General Hospital (1) University of Washington (1) University Hospital, Limoges (1) The Netherlands Cancer Institute (1) Sohag University (1) Children's Mercy Hospital Kansas City (1) Aspargo Labs (1) Stanford University (1) Mostafa Bahaa (1) M.D. Anderson Cancer Center (1) University Hospital, Rouen (1) Assistance Publique - Hôpitaux de Paris (1) Vastra Gotaland Region (1) VA Office of Research and Development (1) Mezzion Pharma (1) Mansoura University (1) Rennes University Hospital (1) University of Pennsylvania (1) Ihab Elsayed Hassan (1)
PDE4A (14) PDE3A (14) ADORA2B (11) ADORA2A (11) SLC29A1 (3) PDE6H (3)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.